Mersana Therapeutics (NASDAQ: MRSN) is one of 291 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Mersana Therapeutics to related companies based on the strength of its risk, valuation, analyst recommendations, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

76.7% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 49.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Mersana Therapeutics and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mersana Therapeutics 0 0 4 0 3.00
Mersana Therapeutics Competitors 1176 3525 12069 248 2.67

Mersana Therapeutics presently has a consensus price target of $23.67, indicating a potential upside of 48.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.74%. Given Mersana Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Mersana Therapeutics is more favorable than its competitors.


This table compares Mersana Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors -5,410.53% -160.10% -35.65%

Valuation & Earnings

This table compares Mersana Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors $290.27 million $35.99 million 70.10

Mersana Therapeutics’ competitors have higher revenue and earnings than Mersana Therapeutics.


Mersana Therapeutics beats its competitors on 7 of the 10 factors compared.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with's FREE daily email newsletter.